GlassScriptPhysician profile
Joseph Peter Talcott
NPI 1134220270
$3,316.80
in general payments reported to CMS, 2019-2025
29 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $435 · 2021: $506 · 2022: $425 · 2023: $561 · 2024: $562 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.07 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $834.69 | 2019-2023 | Orilissa, Lo Loestrin Fe, Viberzi |
| Novo Nordisk INC | $717.18 | 2019-2025 | Wegovy, Saxenda |
| Astellas Pharma US INC | $437.54 | 2019-2025 | Veozah |
| Daiichi Sankyo INC. | $261.75 | 2021-2025 | Injectafer |
| Lupin INC. | $155.56 | 2019-2020 | |
| Exeltis, USA INC. | $140.44 | 2021-2025 | Slynd |
| Lilly USA, LLC | $118.66 | 2023-2025 | Zepbound |
| Mayne Pharma Commercial LLC | $98.58 | 2023-2025 | |
| Mylan Pharmaceuticals INC. | $72.42 | 2021-2022 | |
| Biogen, INC. | $50.53 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $44.79 | 2021-2024 | |
| Aspira Women'S Health INC | $43.12 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.26 | 2020 | |
| Therapeuticsmd, INC. | $37.18 | 2019 | |
| Scynexis, INC. | $24.77 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $24.63 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.58 | 2019 | |
| Sage Therapeutics, LLC | $20.87 | 2020 | |
| Sumitomo Pharma America, INC. | $18.58 | 2024 | Gemtesa |
| Olympus America INC. | $17.85 | 2019 | |
| Shield Therapeutics INC | $17.08 | 2024 | |
| Axonics, INC. | $16.10 | 2021 | |
| Minerva Surgical, INC | $15.72 | 2020 | |
| Merck Sharp & Dohme LLC | $15.62 | 2019 | |
| Exact Sciences Corporation | $15.31 | 2025 | Cologuard Collection Kit |
| Amag Pharmaceuticals, INC. | $14.68 | 2019 | |
| Acessa Health INC. | $14.27 | 2021 | |
| Organon LLC | $14.00 | 2024 | |
| Allergan, INC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Talcott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.